Anticoagulation is used to treat venous thromboembolism (VTE) in cancer patients, but may be associated with an increased risk of bleeding. VTE recurrence and major bleeding were assessed in cancer patients treated for VTE with the most currently prescribed anticoagulants in clinical practice. Newly diagnosed cancer patients (first VTE 1/1/2013-05/31/2015) who initiated rivaroxaban, low-molecular-weight heparin (LMWH), or warfarin were identified from Humana claims data and observed until end of eligibility or end of data availability. VTE recurrence was a hospitalization with a primary diagnosis of VTE 7 days after first VTE. Major bleeding events on treatment were identified using validated criteria. Cohorts were compared using Kaplan-Meier rates at 6 and 12 months and Cox proportional hazards models. Cohorts were adjusted for their differences at baseline. A total of 2428 patients (rivaroxaban: 707; LMWH: 660; warfarin: 1061) met inclusion criteria. Patient characteristics were well balanced after weighting. There was a trend for lower VTE recurrence rates in rivaroxaban users compared to LMWH users at 6 months (13.2% vs. 17.1%; P 5 .060) and significantly lower at 12 months (16.5% vs. 22.2%; P 5 .030)
| I N TR ODU C TI ON

Venous thromboembolism (VTE), including deep vein thrombosis (DVT)
and pulmonary embolism (PE), is the second leading cause of death for cancer patients. 1 It is estimated that the annual incidence of VTE is approximately 1 out of 200 in a population of cancer patients. 2 When compared to the general population, patients with cancer have a 4.1-fold risk of thrombosis and those undergoing chemotherapy have a 6.5-fold risk. 3, 4 Furthermore, the risk of recurrence after a first episode of VTE is higher in cancer patients than in those without underlying malignancy. 5 Anticoagulant therapy is the key option for treatment and secondary prophylaxis of VTE. Current treatment guidelines recommend anticoagulation with low-molecular-weight heparin (LMWH) for at least 3 to 6 months in patients with cancer. 6, 7 Treatment beyond the initial 6 months should also be considered for patients with metastatic disease and for those receiving chemotherapy. These recommendations are based on previous clinical trials of LMWH and warfarin for the treatment of VTE in cancer patients who showed that LMWH was more effective than warfarin in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding. 8, 9 In practice, many patients with cancer are treated for less than the recommended 3 to 6 months and are not treated with a LMWH. [10] [11] [12] [13] Direct oral anticoagulant (DOAC) agents are approved for VTE treatment but are not yet endorsed by the guidelines for cancerassociated thrombosis due to lack of clinical evidence in this patient population. A subgroup analysis of patients with cancer from the EIN-STEIN randomized trials, who had DVT or PE, reported that rivaroxaban had similar efficacy and superior safety relative to warfarin. 14 A recent meta-analysis of randomized controlled trials also found that DOACs were as effective and safe as heparin in combination with vitamin K antagonists (VKAs) for the treatment of VTE in this population.
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Another meta-analysis found that DOACs were as effective and safe as VKAs but may have higher rates of bleeding when compared to LMWH. 16, 17 Limited information exists on the effectiveness of currently prescribed anticoagulants in prevention of VTE recurrence in patients with cancer. The objective of this observational study was to compare the risk of VTE recurrence and major bleeding in cancer patients treated with anticoagulants for VTE in a real-world setting. 
| M E TH ODS
| Statistical analysis
Descriptive analyses were conducted to compare patient demographics and baseline clinical characteristics between groups. Mean, standard deviation, and median were reported for continuous variables; frequency and proportion were reported for categorical variables. Statistical differences between groups were assessed using standardized differences.
Three comparisons were performed among the anticoagulant agents: LMWH compared to rivaroxaban, LMWH compared to warfarin, and rivaroxaban compared to warfarin. To reduce the potential for confounding between groups, the inverse probability of treatment weights (IPTW) approach was used based on propensity scores for each comparison. Weighting patients by the inverse probability of the treatment received creates a synthetic sample independent of the baseline covariate. 19 Each patient was assigned a weight such that, in the weighted pseudo-population, the distribution of measured confounders was similar between the compared treatment groups. To calculate IPTWs, the probability (i.e., the propensity score) of receiving Kaplan-Meier curves for time from the index date to first recurrent VTE event were compared between groups in the IPTW-weighted populations. Kaplan-Meier rates for VTE recurrences at 6 and 12 months after the index date were compared between groups using logrank tests. For the major bleeding analysis, Kaplan-Meier rates at 3 and 6 months were evaluated and compared between groups.
Weighted Cox proportional hazards models (i.e., time to event analysis) were used to compare the time to recurrence or major bleeding between groups. Patients were censored at the end of the observation period if no event occurred. Nonparametric bootstrap procedures with 499 replications were used to estimate 95% confidence intervals (CIs)
and P-values.
| R E SU LTS
| Patient characteristics
A total of 2428 cancer patients who developed a VTE and were treated with anticoagulant agents within 7 days of VTE diagnosis were identified, including 1061 treated with warfarin, 707 with rivaroxaban, and 660 with LMWH. Median duration of therapy with LMWH (1.0 month) was shorter than for rivaroxaban (3.0 months) and warfarin (3.5 months). Weighted groups were similar in terms of baseline characteristics ( Table 1 ). The mean age was 73 years and about half of patients were women. PE represented between 25% to 30% of the index VTE and DVT represented between 55% and 60%. The remaining 13% to 15% of patients were diagnosed with both PE and DVT. About 10% of patients were diagnosed with a cancer type (stomach, pancreas, or brain) associated with a very high risk of developing VTE and onethird were diagnosed with a cancer type (lung, lymphatic, gynecologic, bladder, testicular, or renal) associated with a high risk of developing VTE. Prior surgeries, 13 including major surgery, abdominopelvic surgery, and neurosurgery or orthopedic surgery, as well as provoked VTE, 13 were also generally similar between groups. Some differences were observed in selected comorbidities; patients in the LMWH group had lower rates of hypertension, COPD, and diabetes compared to patients in the rivaroxaban or warfarin groups during the 6-month baseline period.
| VTE recurrence
During the follow-up period, 13% of patients treated with rivaroxaban, 18% of patients treated with LMWH, and 18% of patients treated with warfarin experienced a recurrent VTE event ( 
| Bleeding events
Rates of major bleeding for LMWH and rivaroxaban users were 8.3%
and 8.2%, respectively, at 6 months, with an HR of 1.03 (95% CI: 0.64-1.65; P 5 .917; Table 2 and Figure 2 ). In the comparison between LMWH and warfarin users, major bleeding rates were 8.5% and 8.6%, respectively, at 6 months with an HR of 1.04 (95% CI: 0.69-1.57; P 5 .836). The rate of major bleeding was also similar for rivaroxaban and warfarin users-9.0% and 8.7%, respectively, at 6 months with an HR of 1.01 (95% CI: 0.71-1.43; P 5 .961). The majority of bleeding events were gastrointestinal in each group (Supporting Information   Table S1 ).
To understand the rates of major bleeding that are not related to anticoagulation in patients with cancer, a pooled cohort of patients treated with all three anticoagulants (2428) were matched to cancer patients who did not have VTE nor received anticoagulation. The rates of major bleeding at 3 months were 5.9% and 2.6% in the anticoagulated and control cohorts, respectively. At 6 months, the rates were 8.7% and 4.2% in the anticoagulated and control cohorts, respectively. were differences in the magnitude of risk reduction between the two studies. The CLOT study reported a 52% lower risk of recurrent VTE in patients receiving dalteparin when compared to warfarin over a 6-month study period (P 5 .002). 8 The CATCH study reported a 35% decreased risk of VTE in patients receiving tinzaparin when compared to warfarin over a 6-month study period, but the result did not reach statistical significance (P 5 .07). 9 With respect to bleeding risk, the rates of major bleeding in the LMWH and warfarin arms of CLOT and CATCH were similar to the findings reported in the current study. One potential explanation for the inferior efficacy of LMWHs observed in the current study is that patients are suboptimally treated in real-world settings. The median duration of therapy with LMWHs (1 month) was significantly shorter than with oral anticoagulants such as rivaroxaban (3 months) and warfarin (3.5 months). This trend is in line with other studies reporting that the duration of therapy for LMWH tends to be shorter than for oral anticoagulants [10] [11] [12] 20 and, furthermore, suggests that most cancer patients on LMWH are not getting the generally recommended 3 to 6 months of treatment in a real-world clinical practice setting. In addition, a separate large claims analysis also has reported a higher persistence rate at 6 months for oral anticoagulants among cancer patients when compared to LMWHs (61% vs. 37%). 13 A reason patients may be stopping treatment with LMWH early could be the higher cost of the injectable as compared to the oral agents. Injectable medications are usually set at a higher copay than oral medications, so patients may consider discontinuing LMWH if the copay proves cost prohibitive. 21 The cumulative rates for major bleeding at 6 months observed in the current study (8.5%) appear similar to those reported in the CLOT study (4-6%) and higher than those reported in the CATCH study (3%). 8 This discrepancy between the two randomized controlled trials and the current study may be explained, in part, by differences in patient demographics. Patients in the current study cohorts were generally older than in the randomized trials, with a mean population age of 73 years compared to 63 years in CLOT and 59 years in CATCH. In addition, many patients in this study had comorbidities that are known risk factors for bleeding, such as hypertension (65-75%), liver disease (13-21%), renal disease (13-20%), congestive heart failure (12-15%),
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and diabetes (26-33%). 
